Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as import...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Pavel A, Dowell, Jonathan E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391166/
https://www.ncbi.nlm.nih.gov/pubmed/28435296
http://dx.doi.org/10.2147/OTT.S113598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391166/
https://www.ncbi.nlm.nih.gov/pubmed/28435296
http://dx.doi.org/10.2147/OTT.S113598

Ejemplares similares